← The Wire
ACRVNasdaq
Acrivon Therapeutics, Inc.
Pharmaceutical Preparations · CIK 1781174
Develops precision oncology medicines matched to patients via a proteomics-based platform
red 8-K · 90d
$63M
Market cap
$1.78
Last close
+6.0%
1D
+12.7%
5D
463K
Volume
Price · last 39 sessions-18.0%
May 4L $1.38 · H $2.17Jun 29
76
Total filings
Jun 17, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteJun 17, 2026DEFA14ADEFA14AMay 22, 202610-Q10-QMay 13, 20268-KResults of OperationsMay 13, 2026DEFA14ADEFA14AApr 30, 2026DEF 14ADEF 14AApr 30, 2026SC 13D/ASC 13D/AApr 23, 2026SC 13D/ASC 13D/AMar 23, 20268-KResults of Operations · Reg FD DisclosureMar 19, 202610-K10-KMar 19, 20268-KAgreement TerminatedMar 2, 20268-KReg FD DisclosureFeb 27, 20268-KReg FD DisclosureJan 8, 20268-KResults of Operations · Reg FD DisclosureJan 8, 202610-Q10-QNov 13, 20258-KResults of OperationsNov 13, 20258-KReg FD DisclosureSep 5, 202510-Q10-QAug 13, 20258-KResults of OperationsAug 13, 20258-KShareholder VoteJun 13, 202510-Q10-QMay 14, 20258-KResults of OperationsMay 14, 2025DEFA14ADEFA14AApr 25, 2025DEF 14ADEF 14AApr 25, 20258-KReg FD DisclosureApr 7, 20258-KReg FD DisclosureMar 27, 202510-K10-KMar 27, 20258-KResults of Operations · Reg FD DisclosureMar 25, 20258-KExecutive ChangeMar 14, 202510-Q10-QNov 13, 20248-KResults of OperationsNov 13, 20248-KReg FD Disclosure · Company UpdateOct 11, 20248-KReg FD Disclosure · Company UpdateSep 16, 20248-KResults of OperationsAug 13, 202410-Q10-QAug 13, 20248-KShareholder VoteJun 21, 20248-KResults of OperationsMay 14, 202410-Q10-QMay 14, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 20248-KResults of Operations · Reg FD DisclosureApr 24, 20248-KMaterial Agreement · Equity IssuanceApr 9, 20248-KResults of OperationsMar 28, 202410-K10-KMar 28, 20248-KExecutive ChangeMar 4, 20248-KExecutive ChangeFeb 8, 20248-KReg FD DisclosureJan 8, 20248-KMaterial AgreementDec 8, 20238-KResults of Operations · Reg FD DisclosureNov 9, 202310-Q10-QNov 9, 20238-KReg FD DisclosureSep 5, 20238-KResults of OperationsAug 11, 202310-Q10-QAug 11, 20238-KShareholder VoteJun 22, 20238-KMaterial AgreementJun 5, 20238-KResults of OperationsMay 9, 202310-Q10-QMay 9, 2023DEFA14ADEFA14AMay 1, 2023DEF 14ADEF 14AMay 1, 20238-KReg FD DisclosureMay 1, 20238-KResults of OperationsMay 1, 20238-KReg FD DisclosureApr 25, 202310-K10-KMar 28, 20238-KResults of OperationsMar 28, 20238-KResults of Operations · Reg FD DisclosureMar 13, 20238-KCompany UpdateMar 3, 2023SC 13GACRIVON THERAPEUTICS, INC.Feb 14, 202310-Q10-QDec 15, 2022SC 13DSC 13DNov 28, 2022SC 13GSCHEDULE 13GNov 28, 2022SC 13GSC 13GNov 25, 2022SC 13GSC 13GNov 21, 2022SC 13GSC 13GNov 18, 20228-KEquity Issuance · Bylaw AmendmentNov 17, 2022424B4424B4Nov 16, 2022S-1/AS-1/ANov 8, 2022S-1/AS-1/ANov 3, 2022S-1S-1Oct 17, 2022
Insider Activity
◆ Cluster Buy · 3 insidersIn the 90 days to Jan 14, 2026: 3 insiders bought $115K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 14, 2026 | Blume-Jensen PeterPresident and CEO | Buy | 49,000 | $1.68 | $82K |
| Jan 14, 2026 | Levy Adam D.Chief Financial Officer | Buy | 8,832 | $1.70 | $15K |
| Jan 13, 2026 | Devroe EricChief Operating Officer | Buy | 10,000 | $1.72 | $17K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance